The Patent Finder

Innate Pharma, S.A.

6 patents currently held · Updated Nov 21, 2026
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

5
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 30, 2026
    The maintenance fee for Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders (US 9,067,997) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,732,131Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
In force
 · USPTO record
In forceUSPTO record
US 10,160,810Monoclonal antibodies against NKG2A
In force
 · USPTO record
In forceUSPTO record
US 7,803,376Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using NK Cell Potentiating Compounds
In force
 · High confidence
In forceHigh confidence
US 8,993,319Monoclonal antibodies against NKG2A
In force
 · USPTO record
In forceUSPTO record
US 8,222,376Kir-Binding Agents and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,067,997Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 6: 11 patents in force now held by others · 12 lapsed for an unpaid fee · 10 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 abandoned · 20 no status recorded

Showing 1 to 10 of 26, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
16/226,742Dec 20, 2018No status recorded
14/829,170Human Anti-Kir AntibodiesAug 18, 2015Abandoned
14/753,886Jun 29, 2015No status recorded
14/659,045Human Anti-Kir AntibodiesMar 16, 2015Abandoned
14/594,322Jan 12, 2015No status recorded
13/912,333Jun 7, 2013No status recorded
13/082,520Transgenic Animals and Methods of Making Recombinant AntibodiesApr 8, 2011Abandoned
13/036,240Feb 28, 2011No status recorded
12/824,685Jun 28, 2010No status recorded
12/728,303Mar 22, 2010No status recorded
10 of 26 applications shown.
Pro members see all 26 published applications.
Pro members: see all 26 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited